TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2859703

Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol once daily for 3 weeks
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol in combination with 12.5 mg chlorthalidone for 3 weeks
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol in combination with 25 mg chlorthalidone for 3 weeks
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol or in combination with 12.5 mg or 25 mg CT for up to 12 months
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Combination therapy with 25 mg CT
Number of subjects: 143
Study: 29552766

Group type: EXPERIMENTAL
Intervention: Endostar combined with cisplatin/pemetrexed chemotherapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Chemotherapy alone (pemetrexed and cisplatin)
Number of subjects: 128
Study: 27314599

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI (effect‐site concentration=1.5 ng.mL‐1)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI
Number of subjects: 218
Study: 24850188

Group type: EXPERIMENTAL
Intervention: SOC + messaging intervention
Number of subjects: 469

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 469
Study: 23121149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: 600 mg GEn
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: 900 mg GEn
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: 1200 mg GEn
Number of subjects: 474
Study: 19735259

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Baseline (untreated)
Number of subjects: 6
Study: 18462268

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonselective β‐blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonselective β‐blockers (with isosorbide‐5‐mononitrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of nonselective β‐blockers and EBL
Number of subjects: 0
Study: 16170124

Group type: EXPERIMENTAL
Intervention: Base-in prism glasses
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo reading glasses
Number of subjects: 72
Study: 12855311

Group type: EXPERIMENTAL
Intervention: IA ketamine 10mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: IA saline 10ml
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intra-muscular ketamine 10mg
Number of subjects: 45
Study: 10543581

Group type: EXPERIMENTAL
Intervention: Spinal manipulation for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dimethicone for 2 weeks
Number of subjects: 0
Study: 8720816

Group type: EXPERIMENTAL
Intervention: Version 2 (manipulated frequency descriptors)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Version 3 (introduction with general information on side effects)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Version 1 (original side effects information)
Number of subjects: 97
Study: 2049361

Group type: EXPERIMENTAL
Intervention: Combination sedation technique using nalbuphine and midazolam
Number of subjects: 2

Group type: COMPARATOR
Intervention: Midazolam sedation alone
Number of subjects: 2
Study: 6755207

Group type: EXPERIMENTAL
Intervention: Regimens with second-line drugs (cytosine arabinoside and asparaginase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous mercaptopurine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified induction period with less immunosuppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuous mercaptopurine (1-week gaps each month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boys with ALL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cell-typing by the FAB system
Number of subjects: 0
Study: 31651842

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone, administered twice daily for 48 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 48 hours
Number of subjects: 80
Study: 27633946

Group type: EXPERIMENTAL
Intervention: Combined tranexamic acid (IV and topical)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (IV)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intraarticular tranexamic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 200
Study: 26417720

Group type: EXPERIMENTAL
Intervention: PCST/exercise
Number of subjects: 222
Study: 24607889

Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment (percutaneous plate via sinus tarsi approach)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine treatment (open reduction and internal fixation with conventional plate via L-shaped lateral approach)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 22210018

Group type: EXPERIMENTAL
Intervention: AMG 386 (3 or 10 mg/kg once weekly)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: AMG 386 (15 mg/kg once weekly)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 19494090

Group type: EXPERIMENTAL
Intervention: Coach-delivered targeted exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual behaviour (control)
Number of subjects: 0
Study: 17465000

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a and ribavirin for 48 weeks
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a and ribavirin for 24 weeks
Number of subjects: 234
Study: 14725849

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) with GABAergic mechanisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) with glutamate reduction mechanisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with sustained effects on neuronal mechanisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with use-dependent impact on sodium or calcium channels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs with multiple mechanisms of action
Number of subjects: 0
Study: 12027911

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 1265
Study: 9799053

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg) pre-treatment for 4 days and co-administration with cerivastatin (0.3 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cerivastatin (0.3 mg) alone
Number of subjects: 12
Study: 7643540

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 73
Study: 2677610

Group type: EXPERIMENTAL
Intervention: 15% omega-3 diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 7.5% omega-3 diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: omega-3 diet (various sequences)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid diet in healthy controls
Number of subjects: 27
Study: 352184

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo intravenous injection
Number of subjects: 20
Study: 30291760

Group type: EXPERIMENTAL
Intervention: Living with at least one other adult in the household
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Greater number of adults in the house
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Fewer family hassles
Number of subjects: 137
Study: 28506937

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 78
Study: 25447301

Group type: EXPERIMENTAL
Intervention: 1M sucrose solution (SU)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Artificial saliva (AS)
Number of subjects: 49
Study: 23895849

Group type: EXPERIMENTAL
Intervention: Aneurysm clipping and partial blood clot removal in the subarachnoid space
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aneurysm clipping and blood clot removal
Number of subjects: 0
Study: 21463074

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) with Standard Care (SC)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Standard Care (SC) alone
Number of subjects: 393
Study: 19555360

Group type: EXPERIMENTAL
Intervention: 3-month oral function promotion programme including facial muscle and tongue exercises and salivary gland massages
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 141
Study: 16540101

Group type: EXPERIMENTAL
Intervention: Direct gaze
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Averted gaze
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct gaze and averted gaze
Number of subjects: 0
Study: 15692318

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement (400 IU vitamin E, 1 g vitamin C, 90 µg selenium per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 18
Study: 11928800

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy‐based regimens
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vaccine therapy
Number of subjects: 67
Study: 9819503

Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (Group II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent cold crystalloid cardioplegia (Group I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 7522487

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) as part of induction treatment for good-prognosis patients
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Melphalan plus interferon (MP+IFN)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Melphalan plus prednisone (MP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Maintenance treatment with interferon (IFN)
Number of subjects: 78
Study: 2572145

Group type: EXPERIMENTAL
Intervention: Alpidem (150 mg/day, 50 mg t.i.d. for 3 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 4563483

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 60 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 150 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29474208

Group type: EXPERIMENTAL
Intervention: Girls Active intervention group
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1734
Study: 28340073

Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) based empirical left atrial appendage (LAA) isolation in addition to pulmonary vein isolation (PVI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) only
Number of subjects: 100
Study: 25747273

Group type: EXPERIMENTAL
Intervention: Immunotherapy with activated CIK cells (injection of 6.4 × 10(9) autologous CIK cells, 16 times during 60 weeks)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Immunotherapy with activated CIK cells
Number of subjects: 230
Study: 23026547

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 188
Study: 21114826

Group type: EXPERIMENTAL
Intervention: Specialist depression disorder team (psychiatrist and psychotherapist jointly assessing and providing algorithm based drug and psychological treatment)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual secondary care treatment
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Specialist depression disorder team
Number of subjects: 174
Study: 18067986

Group type: EXPERIMENTAL
Intervention: Diabetes-specific ONS (Diasip)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard ONS
Number of subjects: 40
Study: 17093281

Group type: EXPERIMENTAL
Intervention: Cancer control strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer follow-up care guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research on cancer survivorship
Number of subjects: 0
Study: 12888141

Group type: EXPERIMENTAL
Intervention: Index of myocardial performance (IMP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Isovolumic contraction time (IVCT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Isovolumic relaxation time (IVRT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Doppler intervals
Number of subjects: 50
Study: 10643405

Group type: EXPERIMENTAL
Intervention: Palm grip (P)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Finger grip (F)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Surgical haemostat clamp (H)
Number of subjects: 9
Study: 8896726

Group type: COMPARATOR
Intervention: Blacks (n = 45)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Whites (n = 492)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Hispanics (n = 278)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Asians (n = 58)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Asians with hepatitis B excluded (n = 43)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Hepatitis B surface antigen positive Asians (n = 15)
Number of subjects: 938

Group type: COMPARATOR
Intervention: PRA < 10% (n = 339)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Positive antidonor flow cytometry crossmatch (> 30 mean channel shifts, n = 76)
Number of subjects: 938

Group type: COMPARATOR
Intervention: 0 DR mismatches
Number of subjects: 938

Group type: COMPARATOR
Intervention: 1 DR mismatches
Number of subjects: 938

Group type: COMPARATOR
Intervention: 2 DR mismatches
Number of subjects: 938
Study: 1829879

Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ceftazidime combined with teicoplanin
Number of subjects: 120
Study: 7051741

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TNS) over low-back and suprapubic region
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no TNS, only conventional methods)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TNS and conventional methods
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no TNS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TNS and control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neonates from both groups
Number of subjects: 24
Study: 30998770

Group type: EXPERIMENTAL
Intervention: SegNet method
Number of subjects: 0

Group type: COMPARATOR
Intervention: FCN method
Number of subjects: 0

Group type: COMPARATOR
Intervention: U-Net method
Number of subjects: 0
Study: 29907887

Group type: EXPERIMENTAL
Intervention: YH4808 (300 mg) after a single dose at fed state with a standard meal
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: YH4808 (300 mg) after a single dose at fed state with a high-fat meal
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: YH4808 (100 mg) after multiple dosing for 7 days in fed state with a standard meal
Number of subjects: 2
Study: 26098401

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Relaxation Therapy (RT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Historical group (retrospective data)
Number of subjects: 26
Study: 24435507

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10, 5, 5 mg/kg every 24 h)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral indomethacin (0.20‐0.25 mg/kg every 24 h)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (early postnatal age <8 days)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral indomethacin (early postnatal age <8 days)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (neonates >28 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral indomethacin (neonates >28 weeks)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (birth weight >1,000 g)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral indomethacin (birth weight >1,000 g)
Number of subjects: 83
Study: 22000982

Group type: EXPERIMENTAL
Intervention: Short-AVCP group (<64 ms, n = 3)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Long-AVCP group (>64 ms, n = 4)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Short-AVCP group
Number of subjects: 7
Study: 19188808

Group type: EXPERIMENTAL
Intervention: Submaximal exercise session (25-min cycling)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (25-min seated at rest)
Number of subjects: 13
Study: 17967610

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 200

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 200
Study: 16215965

Group type: EXPERIMENTAL
Intervention: REX-DIR gated
Number of subjects: 12

Group type: COMPARATOR
Intervention: REX-DIR non-gated
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IOSB gated
Number of subjects: 12

Group type: COMPARATOR
Intervention: IOSB non-gated
Number of subjects: 12
Study: 11865834

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1600 mg daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10588294

Group type: EXPERIMENTAL
Intervention: Structural Mean Model (SMM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ordinary Least-Squares (OLS) estimator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline covariates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Run-in period
Number of subjects: 0
Study: 7762854

Group type: EXPERIMENTAL
Intervention: N2O (50%) and 0.5 MAC sevoflurane (1%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.0 MAC sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: N2O (60%) and 0.5 MAC isoflurane (0.6%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.0 MAC isoflurane
Number of subjects: 40
Study: 2324941

Group type: EXPERIMENTAL
Intervention: Distracting-active response condition
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Distracting-passive response condition
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ruminative-active response condition
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ruminative-passive response condition
Number of subjects: 69
Study: 7439477

Group type: EXPERIMENTAL
Intervention: SADBE (squaric acid dibutylester) applied weekly to one side of the head
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: SADBE (squaric acid dibutylester)
Number of subjects: 53
Study: 30165506

Group type: EXPERIMENTAL
Intervention: Cluster robustness score with increasing amounts of noise (zero mean and increasing variance)
Number of subjects: 0
Study: 29960684

Group type: EXPERIMENTAL
Intervention: High-dose radiotherapy (RT) at 60 Gy
Number of subjects: 56
Study: 27388492

Group type: EXPERIMENTAL
Intervention: Imagery training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Perceptual-motor training (PMT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 36
Study: 25316463

Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdentures
Number of subjects: 50
Study: 22532781

Group type: EXPERIMENTAL
Intervention: Mirena((R)) for 5 years (in patients not submitted to endometrial resection)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Mirena((R)) after endometrial resection
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 89
Study: 19965532

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG) insertion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Anatomical landmark-guided technique (ALT)
Number of subjects: 110
Study: 17937690

Group type: EXPERIMENTAL
Intervention: B221 (2 g every 5 hours for 3 days)
Number of subjects: 240
Study: 15045043

Group type: EXPERIMENTAL
Intervention: HFA‐BDP 800 microg/day
Number of subjects: 141

Group type: COMPARATOR
Intervention: CFC‐BDP 1500 microg/day
Number of subjects: 141
Study: 11665810

Group type: EXPERIMENTAL
Intervention: Red Bull Energy Drink
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control drinks
Number of subjects: 36
Study: 9840605

Group type: EXPERIMENTAL
Intervention: Intravenous ARTS (120 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral ARTS (100 mg)
Number of subjects: 12
Study: 8130815

Group type: EXPERIMENTAL
Intervention: Anorectic subjects (BMI: 14.5 ± 0.8 kg/m²)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy volunteers (BMI: 20.3 ± 0.5 kg/m²)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI: 33.0 ± 0.9 kg/m²)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anorectic subjects
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 32
Study: 2781110

Group type: EXPERIMENTAL
Intervention: diatrizoate (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ioxaglate (group IIA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ioxaglate (group IIB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iohexol (group III)
Number of subjects: 60
Study: 945686

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo suppository control group
Number of subjects: 20
Study: 30586727

Group type: EXPERIMENTAL
Intervention: ABC-stroke score
Number of subjects: 8705

Group type: EXPERIMENTAL
Intervention: ABC-bleeding score
Number of subjects: 8705

Group type: EXPERIMENTAL
Intervention: Edoxaban treatment
Number of subjects: 8705

Group type: EXPERIMENTAL
Intervention: Elevated hsTnT, NT-proBNP, and GDF-15
Number of subjects: 8705

Group type: EXPERIMENTAL
Intervention: Elevated hsTnT and GDF-15
Number of subjects: 8705
Study: 27522513

Group type: EXPERIMENTAL
Intervention: Spironolactone (100mg once before surgery, then 25mg on postoperative days 0, 1, and 2)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 233